
Newron Announces Approval For Pivotal Phase III ENIGMA-TRS Program With Evenamide As Add-On Therapy In Patients With ...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS) 12.05.2025 / 07:00 CET/ …